• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
  

PubMed=2785141; DOI=10.4049/jimmunol.142.9.3329
Timothy L. Darrow, Craig L. Slingluff Jr., Hilliard Foster Seigler;
The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
J. Immunol. 142:3329-3335(1989)

PubMed=2404572
Nancy J. Crowley, Craig L. Slingluff Jr., Timothy L. Darrow, Hilliard Foster Seigler;
Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
Cancer Res. 50:492-498(1990)

PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162
Craig L. Slingluff Jr., Teresa A. Colella, Lee Thompson, D. David Graham, Jonathan C.A. Skipper, Jennifer Caldwell, Larry Brinckerhoff, David J. Kittlesen, Donna H. Deacon, Correen Oei, Nancy L. Harthun ...Show all 15 authors... , Eric L. Huczko, Donald Frederick Hunt, Timothy L. Darrow, Victor H. Engelhard; Show fewer authors
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Cancer Immunol. Immunother. 48:661-672(2000)

PubMed=11520076; DOI=10.1006/cimm.2001.1809
Rahima Zennadi, Zeinab Abdel-Wahab, Hilliard Foster Seigler, Timothy L. Darrow;
Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.
Cell. Immunol. 210:96-105(2001)

PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209
Kevin T. Hogan, Michael A. Coppola, Christine L. Gatlin, Lee W. Thompson, Jeffrey Shabanowitz, Donald Frederick Hunt, Victor H. Engelhard, Mark M. Ross, Craig L. Slingluff Jr.;
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.
Cancer Res. 64:1157-1163(2004)

PubMed=19147755; DOI=10.1158/1078-0432.CCR-08-1916
Christina K. Augustine, Jin Soo Yoo, Anil Potti, Yasunori Yoshimoto, Patricia A. Zipfel, Henry Seth Friedman, Joseph R. Nevins, Francis Ali-Osman, Douglas Scott Tyler;
Genomic and molecular profiling predicts response to temozolomide in melanoma.
Clin. Cancer Res. 15:502-510(2009)

PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461
Kerrington R. Molhoek, Amber L. Shada, Mark Smolkin, Sudhir Chowbina, Jason Papin, David L. Brautigan, Craig L. Slingluff Jr.;
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.
Melanoma Res. 21:274-284(2011)

PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389
Brian J. Capaldo, Devin Grimm Roller, Mark J. Axelrod, Alexander F. Koeppel, Emanuel F. Petricoin 3rd, Craig L. Slingluff Jr., Michael J. Weber, Aaron J. Mackey, Daniel Gioeli, Stefan Bekiranov;
Systems analysis of adaptive responses to MAP kinase pathway blockade in BRAF mutant melanoma.
PLoS ONE 10:e0138210.1-e0138210.25(2015)

PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068
Devin Grimm Roller, Brian J. Capaldo, Stefan Bekiranov, Aaron J. Mackey, Mark Robert Conaway, Emanuel F. Petricoin 3rd, Daniel Gioeli, Michael J. Weber;
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Oncotarget 7:2734-2753(2016)